In another phase III clinical trial, the Iressa NSCLC Trial Evaluating Response and Survival Against Taxotere (INTEREST trial), which has met the primary endpoint of noninferiority of gefitinib as compared to docetaxel, patients with high EGFR gene copy numbers receiving gefitinib had a MST of 8.4 months as compared to 7.5 months in those treated with chemotherapy (HR:1.09; 95 %CI 0.78-1.15 P=0.6199) [90]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.